Shopping Cart
- Remove All
- Your shopping cart is currently empty
Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. It exhibits anti-tumor immune effects and can improve metastatic non-small cell lung cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $455 | In Stock | |
5 mg | $1,180 | In Stock | |
10 mg | $1,980 | In Stock | |
25 mg | $2,970 | In Stock | |
50 mg | $3,970 | In Stock | |
100 mg | Inquiry | In Stock |
Description | Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. It exhibits anti-tumor immune effects and can improve metastatic non-small cell lung cancer. |
In vitro | Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 days; CD4 T cells) activates primary human T cells, inducing the secretion of IFNγ, IL-17a, IL-10, IL-9, GM-CSF, TNFα, and IL-21[1]. |
In vivo | Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; twice weekly for 2 weeks) induces tumor regression in the Sa1/N syngeneic mouse tumor model[1]. |
Alias | JTX 2011 |
Molecular Weight | 145.74 kDa |
Cas No. | 2039148-04-2 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.